Drug Profile
Matuzumab
Alternative Names: Anti-EGFR monoclonal antibody; EMD 72000Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator ImClone Systems
- Developer Merck KGaA; Takeda
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Epidermal growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 20 Feb 2008 Takeda together with Merck have decided to jointly discontinue development of matuzumab for all indications
- 20 Feb 2008 Discontinued - Phase-II for Cervical cancer in Europe (IV)
- 20 Feb 2008 Discontinued - Phase-II for Colorectal cancer in European Union (IV)